VVOS logo

VVOS
Vivos Therapeutics Inc

5,483
Mkt Cap
$10.79M
Volume
87,332.00
52W High
$7.95
52W Low
$0.7607
PE Ratio
-0.36
VVOS Fundamentals
Price
$0.8072
Prev Close
$0.8002
Open
$0.8665
50D MA
$1.22
Beta
0.81
Avg. Volume
401,147.96
EPS (Annual)
-$2.06
P/B
-5.03
Rev/Employee
$65,085.82
$32.27
Loading...
Loading...
News
all
press releases
Vivos Therapeutics Inc Full Year Sales Increase
(RTTNews) - Vivos Therapeutics Inc (VVOS) released Loss for full year of -$21.17 million...
Nasdaq News: Markets·16d ago
News Placeholder
More News
News Placeholder
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.read more...
Benzinga·26d ago
News Placeholder
Insider Buying: Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Buys 1,353,625 Shares of Stock
Vivos Therapeutics, Inc. (NASDAQ:VVOS - Get Free Report) major shareholder Michael Skaff purchased 1,353,625 shares of the business's stock in a transaction on Tuesday, March 31st. The stock was...
MarketBeat·29d ago
News Placeholder
Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours
Vivos Therapeutics shares surge 21.21% after hours as a Michigan-based investor group acquires a 19.9% stake through a $2.39 million private placement.read more...
Benzinga·29d ago
News Placeholder
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +323.53% and -84.40%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -86.47% and -23.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of -14.26% and +1.45%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know
Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4mo ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.56% and +14.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
<
1
2
...
>

Latest VVOS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.